The potential deal with the U.S. Department of Defense (DoD) would see Moderna’s mRNA technology being used to develop a vaccine targeting the Ebola strain responsible for the disease’s outbreak in Uganda, according to a report.
https://www.pharmalive.com/wp-content/uploads/2022/09/ReutersModerna9-1-2022.jpg8001200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-10-26 13:01:282022-10-27 09:46:10Moderna close to U.S. deal to make vaccines for Ebola, biological threats
